Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has David R. Spigel's publication output changed over time?
ScholarIQpublication output · 2008–2020
Output grew100% over the shown period — from 1 works in 2008 to 2 in 2020.
1
1
3
1
3
1
2
2008201220152017201820192020
What are the most-cited papers on David R. Spigel?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,730 CitationsOPEN ACCESS
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
New England Journal of Medicine. 20159,504 CitationsOPEN ACCESS
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
New England Journal of Medicine. 20158,599 CitationsOPEN ACCESS
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
New England Journal of Medicine. 20182,828 CitationsOPEN ACCESS
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
The Lancet. 20192,246 Citations
Related on ScholarIQ
Sarah Cannon
Institution
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Paper
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Paper
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Paper
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Paper
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paper